Skip to header Skip to main navigation Skip to main content Skip to footer

Apollo Says AI Has Paid Off Nowhere Outside Tech: The S&P 493 Are Still Flat

Breadcrumb

  • Home
  • Apollo Says AI Has Paid Off Nowhere Outside Tech: The S&P 493 Are Still Flat
Photograph of the carved stone facade of the New York Stock Exchange building with its gold Stock Exchange lettering.

Apollo Global Management's chief economist has put a number on the suspicion many finance chiefs have been voicing privately. In a note published October 24, Torsten Slok argued that artificial intelligence has delivered, in his words, zero financial payoff to corporate America outside of tech. TechCrunch reported the note on October 25. His test is deliberately plain: strip the Magnificent Seven out of the S&P 500, and the remaining 493 companies show flat profit margins, flat revenue per worker, and no sign in the productivity data that AI is moving the needle yet.

The gap in his charts is stark. Revenue per employee at the Magnificent Seven has climbed to roughly 780,000 dollars on an inflation-adjusted basis, against about 525,000 dollars for the S&P 493, and margins sit near 30 percent for the big tech firms against roughly 10 percent for everyone else. Summaries of the note also cite Ramp spending data showing how concentrated the buying still is: the top 10 percent of firms account for 99.5 percent of model serving and inference spend. In other words, the companies selling AI are getting richer from it, a small club of heavy spenders is experimenting at scale, and the broad economy is still waiting.

Slok is skeptical that lag alone explains the gap. He argues it will be hard for ordinary companies to turn increasingly cheap intelligence into higher revenue growth and higher profit margins, because, as he put it, AI may be a great calculator, but in business, intelligence is mostly judgment. He lists what models do not supply on their own: accountability, trust, culture, unwritten rules, ethical trade-offs and fairness, all of which shape reputational risk and, ultimately, revenue. That is a harder critique than the usual deployment complaint, because it questions the product, not just the rollout.

The same weekend brought a useful counterpoint from the vendor side. The Information reported that OpenAI is winning coding work from Anthropic customers with steep discounts, including Replit, on a contract worth more than 100 million dollars a year, and Rippling, where OpenAI's share of engineers' coding work reportedly rose from 16 percent in May to 52 percent while Anthropic's fell from 57 percent to 18 percent. Vendors would not be cutting price that hard if buyers treated frontier capability as priceless. It fits Slok's other observation: mainstream companies are starting to view token spending as a cost center, and many do not need, or will not pay for, the very latest model.

For people building with AI, the lesson is not to stop building. It is to stop selling tokens and start selling measured outcomes. The projects that survive a chief financial officer reading Slok's note are the ones wired into a specific workflow, with a baseline, a human who owns the judgment calls, and a line in the budget that the work visibly moves. Pilots that cannot name the margin, revenue or risk number they are supposed to change are exactly the spending now being questioned. Cheap intelligence is abundant. Deployments that turn it into accountable results are still rare, and that rarity is the business opportunity.

Rocky Mountain Madman LLC
Enterprise AI
AI Implementation
AI Pricing
OpenAI
Anthropic
AI Funding

Ai Industry News

OpenAI Buys Orchestra Bio to Put Agents on the Unglamorous Side of Drug Development

OpenAI announced on Tuesday, October 20, that it has acquired Orchestra Bio, a four-year-old biotech software startup whose AI agents handle the operational grind of drug development. Terms were not disclosed. Orchestra had reportedly raised around 20 million dollars as of 2025 from backers including Andreessen Horowitz, Atria, and 8VC, according to TechCrunch. Its platform helps biotech companies track the minutiae of getting a drug through development, from finances to resolving scheduling problems with clinical trials.

  • Read more about OpenAI Buys Orchestra Bio to Put Agents on the Unglamorous Side of Drug Development

OpenAI Races to Raise 30 Billion Dollars Before Anthropic Sets the Market Price

OpenAI CEO Sam Altman speaking on stage at TechCrunch Disrupt.

OpenAI is accelerating a fundraising round of about 30 billion dollars that could value the company at more than 1.4 trillion dollars, Reuters reported on Monday, citing people familiar with the matter. The push is deliberately timed ahead of Anthropic's expected stock market debut in mid-November. Existing backers SoftBank Group and Abu Dhabi-based MGX are in talks to join, and OpenAI met with long-only funds and sovereign wealth funds last week, in the same week Anthropic was holding its own investor day. OpenAI and SoftBank declined to comment to Reuters.

  • Read more about OpenAI Races to Raise 30 Billion Dollars Before Anthropic Sets the Market Price

Another 45 Billion Dollars: Anthropic and Nscale Are Reportedly Talking About Doing It Again

Anthropic and AI infrastructure provider Nscale are reportedly on the verge of announcing a second compute deal worth 45 billion dollars, according to Bloomberg reporting relayed by TechCrunch on October 19. The talks would come a little over a month after the two companies announced a first 45 billion dollar compute deal. Bloomberg's sources, cited by TechCrunch, cautioned that the talks are still underway and the details could change, and TechCrunch said it had reached out to both companies for comment.

  • Read more about Another 45 Billion Dollars: Anthropic and Nscale Are Reportedly Talking About Doing It Again

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page Next ›
  • Last page Last »

Copyright © 2026 Rocky Mountain Madman LLC - All rights reserved

Developed and Designed by Rocky Mountain Madman LLC